Urotensin II in chronic liver disease: In vivo effect on vascular tone

References

• Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, et al. Cloning of the cDNA encoding the urotensin II precursor in frog and humans reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 1998; 95: 15803–8
   PubMed Web of Science ®Google Scholar
• Pearson D, Shively JE, Clark BR, Geschwind I, Barkley M, Nishioka RS, et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 1980; 77: 5021–4
   PubMed Web of Science ®Google Scholar
• Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999; 401: 282–6
   PubMed Web of Science ®Google Scholar
• Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1999; 1: 383–5
   PubMed Web of Science ®Google Scholar
• Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DL, Jr, et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 1999; 266: 174–8
   PubMed Web of Science ®Google Scholar
• Bern HA, Lederis K. A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts. J Endocrinol 1969;45 Suppl:xi–xii.
   Google Scholar
• Bern HA, Pearson D, Larson BA, Nishioka RS. Neurohormones from fish tails: the caudal neurosecretory system. I. “Urophysiology” and the caudal neurosecretory system of fishes. Recent Prog Horm Res 1985; 41: 533–52
   PubMedGoogle Scholar
• Richards AM, Charles C. Urotensin II in the cardiovascular system. Peptides 2004; 25: 1795–802
   PubMed Web of Science ®Google Scholar
• Thanassoulis G, Huyhn T, Giaid A. Urotensin II and cardiovascular diseases. Peptides 2004; 25: 1789–94
   PubMed Web of Science ®Google Scholar
• Affolter J, Webb DJ. Urotensin II: a new mediator in cardiopulmonary regulation?. Lancet 2001; 358: 774–5
   PubMed Web of Science ®Google Scholar
• Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 2002; 37: 767–72
   PubMed Web of Science ®Google Scholar
• Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 2003; 104: 1–5
   PubMed Web of Science ®Google Scholar
• Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, et al. Role of urotensin II in patients on dialysis. Lancet 2001; 358: 810–1
   PubMed Web of Science ®Google Scholar
• Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation 2002; 106: 2877–80
   PubMed Web of Science ®Google Scholar
• Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG. Plasma urotensin II in heart failure. Lancet 2002; 360: 545–6
   PubMed Web of Science ®Google Scholar
• Russell FD, Meyers D, Galbraith AJ, Bett N, Toth I, Kearns P, et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003; 285: H1576–81
   PubMed Web of Science ®Google Scholar
• Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004; 22: 1341–4
   PubMed Web of Science ®Google Scholar
• Gray GA, Jones MR, Sharif I. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 2001; 69: 175–80
   PubMed Web of Science ®Google Scholar
• Bottrill FE, Douglas SA, Hiley CR, White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 2000; 130: 1865–70
   PubMed Web of Science ®Google Scholar
• MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, et al. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 2000; 30: 201–4
   Google Scholar
• Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000; 131: 1262–74
   PubMed Web of Science ®Google Scholar
• Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A, Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 2004; 109: 1212–4
   PubMed Web of Science ®Google Scholar
• Sondermeijer B, Kompa A, Komesaroff P, Krum H. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 2005; 18: 1195–9
   PubMed Web of Science ®Google Scholar
• Affolter JT, Newby DE, Wilkinson IB, Winter MJ, Balment RJ, Webb DJ. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol 2002; 54: 617–21
   PubMed Web of Science ®Google Scholar
• Wilkinson IB, Affolter JT, de Haas SL, Pellegrini MP, Boyd J, Winter MJ, et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002; 53: 341–7
   PubMed Web of Science ®Google Scholar
• Bohm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002; 135: 25–7
   PubMed Web of Science ®Google Scholar
• Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 1994; 20: 1442–9
   PubMed Web of Science ®Google Scholar
• Newby DE, Jalan R. Urotensin II: better than somatostatin for portal hypertension?. Hepatology 2000; 31: 1201–2
   PubMed Web of Science ®Google Scholar
• Shah V. Cellular and molecular basis of portal hypertension. Clin Liver Dis 2001; 5: 629–44
   PubMedGoogle Scholar
• Kemp W, Roberts SK, Krum H. Urotensin II: a vascular mediator in health and disease. Curr Vascr Pharmacol 2005; 3: 159–68
   PubMedGoogle Scholar
• Abdelrahman AM, Pang CC. Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci 2002; 71: 819–25
   PubMed Web of Science ®Google Scholar
• Lacza Z, DWB. Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig. Life Sci 2006;78:2763–6.
   PubMed Web of Science ®Google Scholar
• Lin L, Ding WH, Jiang W, Zhang YG, Qi YF, Yuan WJ, et al. Urotensin-II activates L-arginine/nitric oxide pathway in isolated rat aortic adventitia. Peptides 2004; 25: 1977–84
   PubMed Web of Science ®Google Scholar
• Zhang AY, Chen YF, Zhang DX, Yi FX, Qi J, Andrade-Gordon P, et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 2003; 285: F792–8
   PubMed Web of Science ®Google Scholar
• Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001; 89: 273–93
   PubMed Web of Science ®Google Scholar
• Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002; 359: 1990–7
   PubMed Web of Science ®Google Scholar
• Hood SG, Watson AM, May CN. Cardiac actions of central but not peripheral urotensin II are prevented by beta-adrenoceptor blockade. Peptides 2005; 26: 1248–56
   PubMed Web of Science ®Google Scholar
• Watson AM, May CN. Urotensin II, a novel peptide in central and peripheral cardiovascular control. Peptides 2004; 25: 1759–66
   PubMed Web of Science ®Google Scholar
• Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T. Depressor and regionally selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 2001; 132: 1625–9
   PubMed Web of Science ®Google Scholar
• Gardiner SM, March JE, Kemp PA, Bennett T. Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response. Br J Pharmacol 2004; 143: 422–30
   PubMed Web of Science ®Google Scholar
• Douglas SA, Dhanak D, Johns DG. From “gills to pills”: urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 2004; 25: 76–85
   PubMed Web of Science ®Google Scholar
• Leonardo G, Arpaia MR, Del Guercio R, Coltorti M. Local deterioration of the cutaneous venoarterial reflex of the hand in cirrhosis. Scand J Gastroenterol 1992; 27: 326–32
   PubMed Web of Science ®Google Scholar
• Seino Y, Ohki K, Nakamura T, Tsukamoto H, Takano T, Aramaki T, et al. Pathophysiological characteristics of cutaneous microcirculation in patients with liver cirrhosis: relationships to cardiovascular hemodynamics and plasma neurohormonal factors. Microvasc Res 1993; 46: 206–15
   PubMed Web of Science ®Google Scholar
• Bircher A, de Boer EM, Agner T, Wahlberg JE, Serup J. Guidelines for measurement of cutaneous blood flow by laser Doppler flowmetry. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis 1994; 30: 65–72
   PubMed Web of Science ®Google Scholar
• Zeghal K, Geslin P, Maurel A, Lagrue G, Lhoste F. Laser-Doppler velocimetry: a new technic for evaluating of microcirculation. A reproducibility study. Presse Med 1986; 15: 1997–2000
   PubMed Web of Science ®Google Scholar
• Stucker M, Heese A, Hoffmann K, Rochling A, Altmeyer P. Precision of laser Doppler scanning in clinical use. Clin Exp Dermatol 1995; 20: 371–6
   PubMed Web of Science ®Google Scholar
• Sundberg S. Acute effects and long-term variations in skin blood flow measured with laser Doppler flowmetry. Scand J Clin Lab Invest 1984; 44: 341–5
   PubMed Web of Science ®Google Scholar
• Okumura H, Aramaki T, Katsuta Y, Terada H, Satomura K, Akaike M, et al. Regional differences in peripheral circulation between upper and lower extremity in patients with cirrhosis. Scand J Gastroenterol 1990; 25: 883–9
   PubMed Web of Science ®Google Scholar
• Roddie IC, Wallace WF. Methods for the assessment of the effects of drugs on the arterial system in man. Br J Clin Pharmacol 1979; 7: 317–23
   PubMed Web of Science ®Google Scholar
• Leifeld L, Clemens C, Spengler U, Sauerbruch T, Heller J. Intrahepatic urotensin II expression is down-regulated in liver cirrhosis. J Hepatology 2005; 42(Suppl 2)69
   Google Scholar